LENZ Therapeutics (LENZ) Competitors $29.00 -0.58 (-1.96%) Closing price 04:00 PM EasternExtended Trading$29.08 +0.08 (+0.27%) As of 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LENZ vs. SWTX, RARE, PTGX, SRRK, ALVO, MTSR, CPRX, VKTX, KYMR, and CRNXShould you be buying LENZ Therapeutics stock or one of its competitors? The main competitors of LENZ Therapeutics include SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Protagonist Therapeutics (PTGX), Scholar Rock (SRRK), Alvotech (ALVO), Metsera (MTSR), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Kymera Therapeutics (KYMR), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry. LENZ Therapeutics vs. Its Competitors SpringWorks Therapeutics Ultragenyx Pharmaceutical Protagonist Therapeutics Scholar Rock Alvotech Metsera Catalyst Pharmaceuticals Viking Therapeutics Kymera Therapeutics Crinetics Pharmaceuticals LENZ Therapeutics (NASDAQ:LENZ) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk, community ranking and profitability. Which has higher valuation and earnings, LENZ or SWTX? LENZ Therapeutics has higher earnings, but lower revenue than SpringWorks Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than SpringWorks Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLENZ TherapeuticsN/AN/A-$124.65M-$1.77-16.38SpringWorks Therapeutics$219.67M16.05-$325.10M-$3.41-13.72 Do analysts rate LENZ or SWTX? LENZ Therapeutics presently has a consensus target price of $46.60, suggesting a potential upside of 60.69%. SpringWorks Therapeutics has a consensus target price of $52.57, suggesting a potential upside of 12.38%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe LENZ Therapeutics is more favorable than SpringWorks Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17SpringWorks Therapeutics 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13 Does the media refer more to LENZ or SWTX? In the previous week, LENZ Therapeutics had 3 more articles in the media than SpringWorks Therapeutics. MarketBeat recorded 5 mentions for LENZ Therapeutics and 2 mentions for SpringWorks Therapeutics. SpringWorks Therapeutics' average media sentiment score of 1.66 beat LENZ Therapeutics' score of 1.10 indicating that SpringWorks Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENZ Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SpringWorks Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more volatility and risk, LENZ or SWTX? LENZ Therapeutics has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Do insiders and institutionals believe in LENZ or SWTX? 54.3% of LENZ Therapeutics shares are held by institutional investors. 6.9% of LENZ Therapeutics shares are held by insiders. Comparatively, 7.8% of SpringWorks Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community believe in LENZ or SWTX? SpringWorks Therapeutics received 91 more outperform votes than LENZ Therapeutics when rated by MarketBeat users. However, 100.00% of users gave LENZ Therapeutics an outperform vote while only 67.95% of users gave SpringWorks Therapeutics an outperform vote. CompanyUnderperformOutperformLENZ TherapeuticsOutperform Votes15100.00% Underperform VotesNo VotesSpringWorks TherapeuticsOutperform Votes10667.95% Underperform Votes5032.05% Is LENZ or SWTX more profitable? LENZ Therapeutics has a net margin of 0.00% compared to SpringWorks Therapeutics' net margin of -134.73%. SpringWorks Therapeutics' return on equity of -46.74% beat LENZ Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LENZ TherapeuticsN/A -58.48% -55.50% SpringWorks Therapeutics -134.73%-46.74%-41.12% SummaryLENZ Therapeutics beats SpringWorks Therapeutics on 10 of the 18 factors compared between the two stocks. Get LENZ Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LENZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LENZ vs. The Competition Export to ExcelMetricLENZ TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$816.23M$3.09B$5.58B$8.50BDividend YieldN/A1.56%5.28%4.17%P/E Ratio-16.3832.6627.1919.64Price / SalesN/A455.28408.78152.17Price / CashN/A168.6838.3234.64Price / Book1.313.366.974.60Net Income-$124.65M-$72.35M$3.23B$248.06M7 Day Performance-9.26%0.32%-0.88%-1.02%1 Month Performance0.14%17.21%7.81%3.51%1 Year Performance55.66%-17.83%31.53%12.68% LENZ Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LENZLENZ Therapeutics1.6563 of 5 stars$29.00-2.0%$46.60+60.7%+58.1%$816.23MN/A-16.38110Positive NewsGap DownSWTXSpringWorks Therapeutics1.5795 of 5 stars$46.75-0.1%$52.57+12.5%+20.4%$3.52B$219.67M-13.43230Positive NewsHigh Trading VolumeRAREUltragenyx Pharmaceutical4.334 of 5 stars$37.04-0.3%$88.77+139.7%-12.0%$3.50B$590.69M-5.841,310Analyst RevisionPTGXProtagonist Therapeutics1.9781 of 5 stars$55.68+2.4%$65.44+17.5%+65.8%$3.45B$207.80M20.93120Insider TradeSRRKScholar Rock4.3998 of 5 stars$34.07-0.5%$42.67+25.2%+254.8%$3.23B$33.19M-14.50140ALVOAlvotech1.737 of 5 stars$10.63-0.3%$18.00+69.3%-30.9%$3.21B$585.60M-5.754Short Interest ↑Gap DownMTSRMetseraN/A$30.39+10.5%$47.00+54.7%N/A$3.19BN/A0.0081News CoverageAnalyst ForecastAnalyst RevisionGap DownHigh Trading VolumeCPRXCatalyst Pharmaceuticals4.7803 of 5 stars$25.84-0.1%$32.83+27.1%+57.2%$3.15B$534.65M21.9080Gap UpVKTXViking Therapeutics4.3985 of 5 stars$27.57-0.9%$87.15+216.1%-45.5%$3.10BN/A-27.5720News CoverageOptions VolumeAnalyst RevisionGap DownKYMRKymera Therapeutics3.3144 of 5 stars$47.16-1.0%$59.82+26.9%+36.7%$3.07B$58.89M-20.15170Gap DownCRNXCrinetics Pharmaceuticals3.5455 of 5 stars$32.28-2.2%$74.56+131.0%-32.7%$3.02B$760K-8.65210Positive NewsAnalyst Revision Related Companies and Tools Related Companies SWTX Competitors RARE Competitors PTGX Competitors SRRK Competitors ALVO Competitors MTSR Competitors CPRX Competitors VKTX Competitors KYMR Competitors CRNX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LENZ) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LENZ Stock Free LENZ Stock Alerts